Publications

Urban JD, Gay EA, Mailman MM. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. (2004). Perfluorooctane sulfonate (PFOS) alters lung development in the neonatal rat. Birth Defects Research, Part A, 70(5), 42.

Perry, C.S. Process for development of protective concentration levels for remediation sites in Texas.Presented at Society for Environmental Toxicology and Chemistry (SETAC) meeting. November 9-13, 2003. Austin, TX.

Staskal, D.F., M.J. DeVito, D.G. Ross, and L.S. Birnbaum. 2003. A Comparison of the metabolism of methoxyresorufin, acetanilide, and caffeine in rat and human CYP1A2 SUPERSOMES. The Toxicologist.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. Caffeine, acetanilide, and methoxyresorufin metabolism by rat and human CYP1A2 SUPERSOMES and their inhibition by 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD). Dioxin 2003, Boston, MA, 2003. Organohalogen Compounds 64:324-327.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. 2003. Caffeine, acetanilide, and methoxyresorufin metabolism by rat and human CYP1A2 SUPERSOMES and their inhibition by 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD). Organohalogen Compounds.

Grasty RC, Grey BE, Lau CS, Rogers JM. 2003. Window of susceptibility to perfluorooctane sulfonate (PFOS)-induced neonatal mortality in the rat. Birth Defects Research, Part B, 68(3), 5.

Perry, C.S. TRRP Rule – The basics part 2: human health PCLs and look-up tables. 2002 TNRCC Environmental Trade Fair presentation and paper.

Grasty RC, Grey BE, Thibodeaux J, Lau C, Rogers JM. (2002). Critical period for increased neonatal mortality induced by perfluorooctane sulfonate (PFOS) in the rat. The Toxicologist 66 (1-S), 118.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. Society of Toxicology 41st Annual Meeting, March 2002.